SK13762003A3 - Deriváty 5-tio-beta-D-xylopyranozidov, spôsob ich prípravy, farmaceutické kompozície tieto deriváty obsahujúce a ich terapeutické použitie - Google Patents

Deriváty 5-tio-beta-D-xylopyranozidov, spôsob ich prípravy, farmaceutické kompozície tieto deriváty obsahujúce a ich terapeutické použitie Download PDF

Info

Publication number: SK13762003A3
Authority: SK; Slovakia
Prior art keywords: formula; group; compound; atom; compounds
Prior art date: 2001-05-11

Application number

SK1376-2003A

Other languages

English (en)

Slovak (sk)

Inventor

V�Ronique Barberousse

Soth Samreth

Original Assignee

Laboratoires Fournier Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-11

Filing date

2002-05-07

Publication date

2004-04-06

2002-05-07 Application filed by Laboratoires Fournier Sa filed Critical Laboratoires Fournier Sa

2004-04-06 Publication of SK13762003A3 publication Critical patent/SK13762003A3/sk

Links

238000002360 preparation method Methods 0.000 title claims description 15
239000008194 pharmaceutical composition Substances 0.000 title claims description 7
230000001225 therapeutic effect Effects 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 74
150000003839 salts Chemical class 0.000 claims abstract description 20
150000004677 hydrates Chemical class 0.000 claims abstract description 11
239000012453 solvate Substances 0.000 claims abstract description 11
125000001424 substituent group Chemical group 0.000 claims abstract description 9
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 6
125000002757 morpholinyl group Chemical group 0.000 claims abstract description 5
125000003386 piperidinyl group Chemical group 0.000 claims abstract description 5
125000000719 pyrrolidinyl group Chemical group 0.000 claims abstract description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 4
125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 4
125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 claims abstract description 3
125000004193 piperazinyl group Chemical group 0.000 claims abstract description 3
125000004076 pyridyl group Chemical group 0.000 claims abstract description 3
125000000217 alkyl group Chemical group 0.000 claims description 15
125000004432 carbon atom Chemical group C* 0.000 claims description 15
239000002253 acid Substances 0.000 claims description 13
-1 atom hydrogen Chemical class 0.000 claims description 9
238000006243 chemical reaction Methods 0.000 claims description 8
238000000034 method Methods 0.000 claims description 8
230000002785 anti-thrombosis Effects 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 6
150000004820 halides Chemical class 0.000 claims description 5
239000001257 hydrogen Substances 0.000 claims description 5
229910052739 hydrogen Inorganic materials 0.000 claims description 5
229910052801 chlorine Inorganic materials 0.000 claims description 4
125000001309 chloro group Chemical group Cl* 0.000 claims description 4
229910014033 C-OH Inorganic materials 0.000 claims description 3
229910014570 C—OH Inorganic materials 0.000 claims description 3
239000003146 anticoagulant agent Substances 0.000 claims description 3
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims description 2
230000017531 blood circulation Effects 0.000 claims description 2
229910052731 fluorine Inorganic materials 0.000 claims description 2
125000001153 fluoro group Chemical group F* 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims description 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
239000000243 solution Substances 0.000 description 29
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 23
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
239000000203 mixture Substances 0.000 description 15
238000002844 melting Methods 0.000 description 13
230000008018 melting Effects 0.000 description 13
239000002904 solvent Substances 0.000 description 13
DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 12
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
239000011541 reaction mixture Substances 0.000 description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
239000000741 silica gel Substances 0.000 description 10
229910002027 silica gel Inorganic materials 0.000 description 10
238000004587 chromatography analysis Methods 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
208000007536 Thrombosis Diseases 0.000 description 7
239000012074 organic phase Substances 0.000 description 7
239000002244 precipitate Substances 0.000 description 7
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
229910000041 hydrogen chloride Inorganic materials 0.000 description 6
229910052943 magnesium sulfate Inorganic materials 0.000 description 6
235000019341 magnesium sulphate Nutrition 0.000 description 6
238000003756 stirring Methods 0.000 description 6
239000000725 suspension Substances 0.000 description 6
FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 5
229940098779 methanesulfonic acid Drugs 0.000 description 5
239000000047 product Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
239000012298 atmosphere Substances 0.000 description 4
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 4
238000005886 esterification reaction Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
229910052500 inorganic mineral Inorganic materials 0.000 description 4
235000010755 mineral Nutrition 0.000 description 4
239000011707 mineral Substances 0.000 description 4
239000002808 molecular sieve Substances 0.000 description 4
150000007524 organic acids Chemical class 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
239000012346 acetyl chloride Substances 0.000 description 3
230000032050 esterification Effects 0.000 description 3
NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 3
238000001914 filtration Methods 0.000 description 3
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
235000005985 organic acids Nutrition 0.000 description 3
238000010992 reflux Methods 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
229960000549 4-dimethylaminophenol Drugs 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
VIWZVFVJPXTXPA-UHFFFAOYSA-N N-(2-Carboxymethyl)-morpholine Chemical compound OC(=O)CN1CCOCC1 VIWZVFVJPXTXPA-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
206010047249 Venous thrombosis Diseases 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
235000019270 ammonium chloride Nutrition 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
150000002430 hydrocarbons Chemical group 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
229930195734 saturated hydrocarbon Natural products 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
YRXIMPFOTQVOHG-UHFFFAOYSA-N 2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetic acid Chemical compound OC(=O)CN(C)C(=O)OC(C)(C)C YRXIMPFOTQVOHG-UHFFFAOYSA-N 0.000 description 1
IPXNXMNCBXHYLQ-UHFFFAOYSA-N 2-pyrrolidin-1-ylacetic acid Chemical compound OC(=O)CN1CCCC1 IPXNXMNCBXHYLQ-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
JRHNIQQUVJOPQC-AQNFWKISSA-N 4-methyl-7-[(2r,3r,4s,5s)-3,4,5-trihydroxythian-2-yl]oxychromen-2-one Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1SC[C@@H](O)[C@H](O)[C@H]1O JRHNIQQUVJOPQC-AQNFWKISSA-N 0.000 description 1
OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
101100481794 Arabidopsis thaliana TOC34 gene Proteins 0.000 description 1
OXGBSZQPLSYVIC-OYYPCOLYSA-N CS(=O)(=O)O[C@]1([C@H](OC(CN(C)C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)CS1)C1=CC2=C(C(=CC(O2)=O)C)C=C1 Chemical compound CS(=O)(=O)O[C@]1([C@H](OC(CN(C)C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)CS1)C1=CC2=C(C(=CC(O2)=O)C)C=C1 OXGBSZQPLSYVIC-OYYPCOLYSA-N 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
206010020608 Hypercoagulation Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
208000003443 Unconsciousness Diseases 0.000 description 1
PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000012300 argon atmosphere Substances 0.000 description 1
JHVLLYQQQYIWKX-UHFFFAOYSA-N benzyl 2-bromoacetate Chemical compound BrCC(=O)OCC1=CC=CC=C1 JHVLLYQQQYIWKX-UHFFFAOYSA-N 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
230000000035 biogenic effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
JGFBRKRYDCGYKD-UHFFFAOYSA-N dibutyl(oxo)tin Chemical compound CCCC[Sn](=O)CCCC JGFBRKRYDCGYKD-UHFFFAOYSA-N 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003480 eluent Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
230000003027 hypercoagulation Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229940087646 methanolamine Drugs 0.000 description 1
MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
FEKRFYZGYUTGRY-UHFFFAOYSA-N n'-ethylmethanediimine Chemical compound CCN=C=N FEKRFYZGYUTGRY-UHFFFAOYSA-N 0.000 description 1
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000000126 substance Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
201000002282 venous insufficiency Diseases 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/06—Benzopyran radicals
- C07H17/065—Benzo[b]pyrans
- C07H17/075—Benzo[b]pyran-2-ones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

SK1376-2003A 2001-05-11 2002-05-07 Deriváty 5-tio-beta-D-xylopyranozidov, spôsob ich prípravy, farmaceutické kompozície tieto deriváty obsahujúce a ich terapeutické použitie SK13762003A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0106236A FR2824559B1 (fr)	2001-05-11	2001-05-11	Nouveaux derives 5-thio-beta-xylopyronasides, procede de preparation, compositions pharmaceutiques les contenant et leur utilisation en therapeutique
PCT/FR2002/001573 WO2002092614A1 (fr)	2001-05-11	2002-05-07	Nouveaux derives 5-thio-ss-d-xylopyranosides, procede de preparation, compositions pharmaceutiques les contenant et leur utilisation en therapeutique

Publications (1)

Publication Number	Publication Date
SK13762003A3 true SK13762003A3 (sk)	2004-04-06

Family

ID=8863165

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1376-2003A SK13762003A3 (sk)	2001-05-11	2002-05-07	Deriváty 5-tio-beta-D-xylopyranozidov, spôsob ich prípravy, farmaceutické kompozície tieto deriváty obsahujúce a ich terapeutické použitie

Country Status (23)

Country	Link
US (1)	US6927209B2 (xx)
EP (1)	EP1385858B1 (xx)
JP (1)	JP2004534036A (xx)
KR (1)	KR20030094351A (xx)
CN (1)	CN1518557A (xx)
AR (1)	AR035880A1 (xx)
AT (1)	ATE323097T1 (xx)
BG (1)	BG108347A (xx)
BR (1)	BR0209102A (xx)
CA (1)	CA2446763A1 (xx)
CZ (1)	CZ20033021A3 (xx)
DE (1)	DE60210595D1 (xx)
EE (1)	EE200300548A (xx)
FR (1)	FR2824559B1 (xx)
HU (1)	HUP0304065A2 (xx)
IL (1)	IL158587A0 (xx)
MX (1)	MXPA03010259A (xx)
NO (1)	NO20034985L (xx)
PL (1)	PL369632A1 (xx)
RU (1)	RU2003132704A (xx)
SK (1)	SK13762003A3 (xx)
WO (1)	WO2002092614A1 (xx)
ZA (1)	ZA200308317B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2860234B1 (fr) *	2003-09-25	2005-12-23	Fournier Lab Sa	Nouveaux derives 666 du thioxylose
WO2006110726A2 (en) *	2005-04-11	2006-10-19	Glaxo Group Limited	Dosage formulations and methods of treatment and prevention
FR2903698B1 (fr) *	2006-07-13	2009-01-30	Fournier S A Sa Lab	Nouveaux derives de 5-thioxylopyranose.
FR2906247B1 (fr) *	2006-09-27	2008-12-26	Fournier S A Sa Lab	Nouveaux derives de 5-thioxylopyranose
FR2906248B1 (fr) *	2006-09-27	2008-12-26	Fournier S A Sa Lab	Nouveaux derives de 5-thioxylopyranose
WO2016054237A2 (en) *	2014-10-03	2016-04-07	Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center	Poly (adp-ribose) polymerase 1 inhibitors structurally unrelated to nad

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE113956T1 (de)	1989-09-22	1994-11-15	Fournier Ind & Sante	Benzopyranon-beta-d-thioxyloside, verfahren zu ihrer herstellung und ihre therapeutische verwendung.

2001
- 2001-05-11 FR FR0106236A patent/FR2824559B1/fr not_active Expired - Fee Related
2002
- 2002-05-06 US US10/139,908 patent/US6927209B2/en not_active Expired - Fee Related
- 2002-05-07 EP EP02738222A patent/EP1385858B1/fr not_active Expired - Lifetime
- 2002-05-07 PL PL02369632A patent/PL369632A1/xx not_active Application Discontinuation
- 2002-05-07 JP JP2002589497A patent/JP2004534036A/ja not_active Withdrawn
- 2002-05-07 AT AT02738222T patent/ATE323097T1/de not_active IP Right Cessation
- 2002-05-07 CA CA002446763A patent/CA2446763A1/fr not_active Abandoned
- 2002-05-07 MX MXPA03010259A patent/MXPA03010259A/es not_active Application Discontinuation
- 2002-05-07 DE DE60210595T patent/DE60210595D1/de not_active Expired - Fee Related
- 2002-05-07 CN CNA028097033A patent/CN1518557A/zh active Pending
- 2002-05-07 RU RU2003132704/04A patent/RU2003132704A/ru not_active Application Discontinuation
- 2002-05-07 HU HU0304065A patent/HUP0304065A2/hu unknown
- 2002-05-07 CZ CZ20033021A patent/CZ20033021A3/cs unknown
- 2002-05-07 SK SK1376-2003A patent/SK13762003A3/sk unknown
- 2002-05-07 KR KR10-2003-7013501A patent/KR20030094351A/ko not_active Withdrawn
- 2002-05-07 BR BR0209102-0A patent/BR0209102A/pt not_active IP Right Cessation
- 2002-05-07 IL IL15858702A patent/IL158587A0/xx unknown
- 2002-05-07 EE EEP200300548A patent/EE200300548A/xx unknown
- 2002-05-07 WO PCT/FR2002/001573 patent/WO2002092614A1/fr not_active Ceased
- 2002-05-08 AR ARP020101682A patent/AR035880A1/es unknown
2003
- 2003-10-24 ZA ZA200308317A patent/ZA200308317B/en unknown
- 2003-11-10 NO NO20034985A patent/NO20034985L/no not_active Application Discontinuation
- 2003-11-11 BG BG108347A patent/BG108347A/bg unknown

Also Published As

Publication number	Publication date
CN1518557A (zh)	2004-08-04
ZA200308317B (en)	2005-03-11
EP1385858A1 (fr)	2004-02-04
NO20034985D0 (no)	2003-11-10
HUP0304065A2 (hu)	2004-04-28
US6927209B2 (en)	2005-08-09
KR20030094351A (ko)	2003-12-11
ATE323097T1 (de)	2006-04-15
RU2003132704A (ru)	2005-04-20
DE60210595D1 (de)	2006-05-24
CA2446763A1 (fr)	2002-11-21
BG108347A (bg)	2004-11-30
US20020198193A1 (en)	2002-12-26
JP2004534036A (ja)	2004-11-11
EE200300548A (et)	2004-02-16
IL158587A0 (en)	2004-05-12
AR035880A1 (es)	2004-07-21
MXPA03010259A (es)	2004-03-10
CZ20033021A3 (en)	2004-04-14
PL369632A1 (en)	2005-05-02
BR0209102A (pt)	2004-07-13
WO2002092614A1 (fr)	2002-11-21
FR2824559A1 (fr)	2002-11-15
NO20034985L (no)	2003-11-10
EP1385858B1 (fr)	2006-04-12
FR2824559B1 (fr)	2004-02-13

Publication	Publication Date	Title
AU780989B2 (en)	2005-04-28	3alpha-hydroxy-3beta methoxymethyl-21-heterocycle substituted steroids with anesthetic activity
KR101046015B1 (ko)	2011-07-01	헤테로고리 화합물 및 이것을 유효성분으로 하는 항종양제
FI95463C (fi)	1996-02-12	Menetelmä anti-tuumoriaineina käyttökelpoisten akryloyylisubstituoitujen pyrrolijohdannaisten valmistamiseksi
EP0351561B1 (en)	1993-10-27	Novel esters of estramustine
SK13762003A3 (sk)	2004-04-06	Deriváty 5-tio-beta-D-xylopyranozidov, spôsob ich prípravy, farmaceutické kompozície tieto deriváty obsahujúce a ich terapeutické použitie
IL144299A (en)	2004-08-31	N-triazolylmethyl-piperazine derivatives as neurokinin receptor antagonists
CN112243437A (zh)	2021-01-19	含丙烯酰基的核转运调节剂及其用途
JPS62187452A (ja)	1987-08-15	環状アミン誘導体
HUP9903526A2 (hu)	2000-06-28	Pirimidinszármazékok és az ezeket tartalmazó gyógyszerkészítmények
CN109422751B (zh)	2022-04-22	一类具有降解酪氨酸蛋白激酶jak3活性的化合物
CN114573504B (zh)	2023-11-14	一种含N-OH键的β-榄香烯衍生物及其制备方法和应用
CN116375601B (zh)	2023-08-04	一种抗黑色素瘤化合物及其制备方法和应用
JPS6323191B2 (xx)	1988-05-16
EP0293146A1 (en)	1988-11-30	Benzofuro [3,2-c] quinoline compounds
PT831092E (pt)	2000-10-31	Derivado de hidroquinona e a sua aplicacao farmaceutica
JP3359722B2 (ja)	2002-12-24	メトトレキセート誘導体
GB2110671A (en)	1983-06-22	1-furyl-3, 4-dihydroisoquinolines
JP4011780B2 (ja)	2007-11-21	ジヒドロキノリン誘導体
JP3000301B2 (ja)	2000-01-17	３−（ビス−置換フェニルメチレン）オキシインド−ル誘導体
PT89103B (pt)	1993-03-31	Processo para a preparacao de novos derivados de labdano e de composicoes farmaceuticas que os contem
CS209950B2 (en)	1981-12-31	Method of making the new 4- amino-6,7-dialcoxy-2-piperazinochinazoline derivatives
WO1999046253A1 (en)	1999-09-16	Heterocyclyl anthracyclinone derivatives
JPH01265070A (ja)	1989-10-23	カルバモイル−２−ピロリジノン化合物
HK1086830B (en)	2009-06-05	Heterocyclic compounds and antitumor drugs containing the same as the active ingredient
JPH1025280A (ja)	1998-01-27	ニトロイミダゾール誘導体